Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

1,721

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

May 31, 2011

Study Completion Date

July 31, 2011

Conditions
Myocardial InfarctionCoronary Disease
Interventions
DRUG

Abciximab + UFH

Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute \[maximum of 10 µg/minute\] infusion for 12 hours)

DRUG

Bivalirudin

Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)

DRUG

Heparin

i.v. bolus of 70 units/kg/body weight of unfractionated heparin

Trial Locations (9)

10249

Vivantes Klinikum im Friedrichshain, Berlin

12157

Vivantes Auguste Viktoria Klinikum, Berlin

12351

Vivantes Klinikum Neukoelln, Berlin

49074

Marienhospital Osnabrueck, Osnabrück

50134

Ospedale Cageggi, Florence

79189

Herz-Zentrum Bad Krozingen, Bad Krozingen

80636

Deutsches Herzzentrum Muenchen, Munich

81675

Medizinische Klinik, Klinikum rechts der Isar, München

97616

Herz- und Gefaessklinik, Kardiologie, Bad Neustadt an der Saale

All Listed Sponsors
lead

Deutsches Herzzentrum Muenchen

OTHER

NCT00373451 - Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome | Biotech Hunter | Biotech Hunter